Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb study of intravenous prasinezumab in early Parkinson's disease
2023-507132-21-00Phase 3Authorised
- Sponsor
- Roche
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in Parkinson's disease (PD) comparing Prasinezumab with Placebo (2 arms). Primary endpoint: Time to confirmed motor progression event. Planned start May 2021; status: authorised.
02
Drugs
prasinezumab
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2023-507132-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507132-21-00.